Skip to content
Engineering Bacteria for Therapeutic Benefit episode artwork

Sep 20, 2018 20 min

Engineering Bacteria for Therapeutic Benefit

from The Bio Report Hosted by Levine Media Group

Synlogic is using synthetic biology to engineer probiotic bacteria to deliver therapeutic benefit. By targeting the microbiome of the gut, the company believes it can produce systemic effects to treat metabolic and other diseases with its new class of therapies it dubs Synthetic Biotics. We spoke to Aoife Brennan, interim CEO and chief medical officer of Synlogic, about the company’s platform technology, how its seeking to exploit the microbiome, and how its engineered bacteria may offer a safer and more effective way to treat certain conditions.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Engineering Bacteria for Therapeutic Benefit

0:00 20:19

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of The Bio Report?

This episode is 20 minutes long.

When was this The Bio Report episode published?

This episode was published on September 20, 2018.

Can I download this The Bio Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.